Progenics Pharmaceuticals Second Quarter Conference Call Set for August 9

Progenics Pharmaceuticals Second Quarter Conference Call Set for August 9

TARRYTOWN, N.Y., Aug. 2, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its
financial results for the second quarter 2013 on Friday, August 9, at 8:30
a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 27841136. A live webcast will be
available in the Media Center of the newly redesigned Progenics website,
www.progenics.com. A replay will be available on the website for two weeks.

Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development. Progenics' first-in-class PSMA targeted
technology platform includes an antibody drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase 2 clinical trials. Among
other assets in its pipeline of targeted radiotherapy and molecular imaging
compounds is Azedra^TM, an ultra-orphan radiotherapy candidate also in phase 2
under an SPA. Progenics' first commercial product, Relistor^®
(methylnaltrexone bromide) for opioid-induced constipation, is partnered with
and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is
developing Relistor in Japan. For additional information, please visit
www.progenics.com.

(PGNX-G)

CONTACT: Kathleen Fredriksen
         Corporate Development
         (914) 789-2871
         kfredriksen@progenics.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.